Tags

Type your tag names separated by a space and hit enter

Postnatal fish oil supplementation in high-risk infants to prevent allergy: randomized controlled trial.
Pediatrics 2012; 130(4):674-82Ped

Abstract

BACKGROUND AND OBJECTIVE

Relative deficiency of dietary omega 3 polyunsaturated fatty acids (n-3 PUFA) has been implicated in the rising allergy prevalence in Westernized countries. Fish oil supplementation may provide an intervention strategy for primary allergy prevention. The objective of this study was to assess the effect of fish oil n-3 PUFA supplementation from birth to 6 months of age on infant allergic disease.

METHODS

In a double-blind randomized controlled trial, 420 infants at high atopic risk received a daily supplement of fish oil containing 280 mg docosahexaenoic acid and 110 mg eicosapentaenoic acid or a control (olive oil), from birth to age 6 months. PUFA levels were measured in 6-month-old infants' erythrocytes and plasma and their mothers' breast milk. Eczema, food allergy, asthma and sensitization were assessed in 323 infants for whom clinical follow-up was completed at 12 months of age.

RESULTS

At 6 months of age, infant docosahexaenoic acid and eicosapentaenoic acid levels were significantly higher (both P < .05) and erythrocyte arachidonic acid levels were lower (P = .003) in the fish oil group. Although n-3 PUFA levels at 6 months were associated with lower risk of eczema (P = .033) and recurrent wheeze (P = .027), the association with eczema was not significant after multiple comparisons and there was no effect of the intervention per se on the primary study outcomes. Specifically, between-group comparisons revealed no differences in the occurrence of allergic outcomes including sensitization, eczema, asthma, or food allergy.

CONCLUSIONS

Postnatal fish oil supplementation improved infant n-3 status but did not prevent childhood allergic disease.

Authors+Show Affiliations

School of Paediatrics and Child Health Research (SPACH), Princess Margaret Hospital, University of Western Australia, PO Box D184, Perth, Western Australia, 6001 Australia.

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22945403

Citation

D'Vaz, N, et al. "Postnatal Fish Oil Supplementation in High-risk Infants to Prevent Allergy: Randomized Controlled Trial." Pediatrics, vol. 130, no. 4, 2012, pp. 674-82.
D'Vaz N, Meldrum SJ, Dunstan JA, et al. Postnatal fish oil supplementation in high-risk infants to prevent allergy: randomized controlled trial. Pediatrics. 2012;130(4):674-82.
D'Vaz, N., Meldrum, S. J., Dunstan, J. A., Martino, D., McCarthy, S., Metcalfe, J., ... Prescott, S. L. (2012). Postnatal fish oil supplementation in high-risk infants to prevent allergy: randomized controlled trial. Pediatrics, 130(4), pp. 674-82. doi:10.1542/peds.2011-3104.
D'Vaz N, et al. Postnatal Fish Oil Supplementation in High-risk Infants to Prevent Allergy: Randomized Controlled Trial. Pediatrics. 2012;130(4):674-82. PubMed PMID: 22945403.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Postnatal fish oil supplementation in high-risk infants to prevent allergy: randomized controlled trial. AU - D'Vaz,N, AU - Meldrum,S J, AU - Dunstan,J A, AU - Martino,D, AU - McCarthy,S, AU - Metcalfe,J, AU - Tulic,M K, AU - Mori,T A, AU - Prescott,S L, Y1 - 2012/09/03/ PY - 2012/9/5/entrez PY - 2012/9/5/pubmed PY - 2012/12/12/medline SP - 674 EP - 82 JF - Pediatrics JO - Pediatrics VL - 130 IS - 4 N2 - BACKGROUND AND OBJECTIVE: Relative deficiency of dietary omega 3 polyunsaturated fatty acids (n-3 PUFA) has been implicated in the rising allergy prevalence in Westernized countries. Fish oil supplementation may provide an intervention strategy for primary allergy prevention. The objective of this study was to assess the effect of fish oil n-3 PUFA supplementation from birth to 6 months of age on infant allergic disease. METHODS: In a double-blind randomized controlled trial, 420 infants at high atopic risk received a daily supplement of fish oil containing 280 mg docosahexaenoic acid and 110 mg eicosapentaenoic acid or a control (olive oil), from birth to age 6 months. PUFA levels were measured in 6-month-old infants' erythrocytes and plasma and their mothers' breast milk. Eczema, food allergy, asthma and sensitization were assessed in 323 infants for whom clinical follow-up was completed at 12 months of age. RESULTS: At 6 months of age, infant docosahexaenoic acid and eicosapentaenoic acid levels were significantly higher (both P < .05) and erythrocyte arachidonic acid levels were lower (P = .003) in the fish oil group. Although n-3 PUFA levels at 6 months were associated with lower risk of eczema (P = .033) and recurrent wheeze (P = .027), the association with eczema was not significant after multiple comparisons and there was no effect of the intervention per se on the primary study outcomes. Specifically, between-group comparisons revealed no differences in the occurrence of allergic outcomes including sensitization, eczema, asthma, or food allergy. CONCLUSIONS: Postnatal fish oil supplementation improved infant n-3 status but did not prevent childhood allergic disease. SN - 1098-4275 UR - https://www.unboundmedicine.com/medline/citation/22945403/Postnatal_fish_oil_supplementation_in_high_risk_infants_to_prevent_allergy:_randomized_controlled_trial_ L2 - http://pediatrics.aappublications.org/cgi/pmidlookup?view=long&amp;pmid=22945403 DB - PRIME DP - Unbound Medicine ER -